|
Pancreatica Trial ID |
Trial Name |
Trial Phase |
Trial Location |
|
|
|
|
|
|
|
|
|
|
|
|
PA-6768 |
Phase
II Study of CPT-11 in Patients with Metastatic, Unresectable
Carcinoid Tumors or Islet Cell Carcinoma. |
Phase 2 |
Houston, TX, US |
|
|
|
|
|
|
PA-6957 |
Phase
II Study of Paclitaxel, Carboplatin and Oral Etoposide Followed
by Weekly Paclitaxel in the Treatment of High-grade Neuroendocrine
Carcinoma. |
Phase 2 |
Huntsville, AL, US
Nashville, TN, US |
|
|
|
|
|
|
PA-7206 |
Phase
I Pilot Study of Flavopiridol in Patients With Locally Advanced
or Metastatic Neuroendocrine Tumors. |
Phase 1 |
Columbus, OH, US |
|
|
|
|
|
|
PA-7298 |
Phase
I/II Pilot Study of Fluorouracil, Leucovorin Calcium, and Oxaliplatin
(FOLFOX) With Bevacizumab in Patients With Advanced Neuroendocrine
Tumors. |
Phase 1 / 2 |
San Francisco, CA, US |
|
|
|
|
|
|
PA-7367 |
Phase
II Study of Capecitabine and Temozolomide For Progressive, Differentiated,
Metastatic Neuroendocrine Cancers. |
Phase 2 |
New York, NY, US |
|
|
|
|
|
|
PA-7537 |
High
Dose Indium-111 Pentetreotide Therapy in Somatostatin Receptor
Expressing Neuroendocrine Neoplasms. |
Phase 3 |
Houston, TX, US |
|
|
|
|
|
|
PA-7538 |
Study
to Investigate the Antiproliferative Effect of Octreotide in
Patients With Metastasized Neuroendocrine Tumors of the Midgut. |
Phase 3 |
Marburg, Germany |
|
|
|
|
|
|
PA-7539 |
Study
of Lanreotide Autogel in Non-Functioning Entero-Pancreatic Endocrine
Tumours. |
Phase 3 |
Vienna, Austria
Prague, Czech Republic
Arhus, Denmark
Belfast, Ireland
Cardiff, England
Edinburgh, England
Glasgow , England
Leeds , England
Leicester , England
London, England
Nottingham, England
Sheffield, England
Clichy, France
Lille , France
Marseille, France
Reims, France
Villejuif , France
Bologna, Italy
Milan, Italy
Zabrze, Poland
Barcelona, Spain |
|
|
|
|
|
|
PA-7540 |
A
Randomized, Double-Blind Placebo-Controlled, Multicenter Phase
III Study in Patients With Advanced Carcinoid Tumor Receiving
Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot
and Placebo. |
Phase 3 |
Fayetteville, AR, US
Little Rock , AR, US
Tucson, AZ, US
Anaheim, CA, US
Los Angeles, CA, US
Aurora, CO, US
Denver, CO, US
Norwich, CT, US
Southington, CT, US
Stamford , CT, US
Ocala, FL, US
Tampa, FL, US
Iowa City, IA, US
Arlington Heights, IL, US
Indianapolis, IN, US
Terry Asher, IN, US
Kansas City, KS, US
Overland Park, KS, US
Louisville, KY, US
Kenner, LA, US
Rochester, MN, US
St. Louis, MO, US
Durham, NC, US
Lebanon, NH, US
Albany, NY, US
New York, NY, US
Cleveland, OH, US
Kettering, OH, US
Philadelphia, PA, US
Charleston, SC, US
Greenville, SC, US
Nashville, TN, US
Austin, TX, US
Corpus Christi, TX, US
Dallas, TX, US
Fort Worth, TX, US
Houston, TX, US
Temple, TX, US
Tyler, TX, US
Norfolk, VA, US
Vancouver, WA, US
Madison, WI, US
Heidelberg, Australia
Herston, Australia
Woodville, Australia |
|
|
|
|
|
|
PA-7541 |
Phase
I/II Study of BB-10901 in Patients With Recurrent or Refractory
Small Cell Lung Cancer, CD56-Positive Small Cell Carcinoma of
Unknown Origin, Other Pulmonary Tumors of Neuroendocrine Origin,
Non-Pulmonary Small Cell Carcinoma, Metastatic Carcinoid Tumor,
or Other CD56+ Solid Tumors (Phase I portion completed; patients
with refractory small cell lung cancer, other pulmonary tumors
of neuroendocrine origin, CD56-negative non-pulmonary small cell
carcinomas, metastatic carcinoid tumors, or other CD56+ solid
tumors are no longer being accrued as of 10/19/2005). |
Phase 2 |
Denver, CO, US
Ocoee , FL, US
Springfield, MA, US
Albany, NY, US
Columbus, OH, US
Kettering, OH, US
Greenville, SC, US
Houston, TX, US
Tyler, TX, US
Norfolk , VA, US
Vancouver, WA, US |
|
|
|
|
|
|
PA-7549 |
Irinotecan
and Cisplatin for High Grade Neuroendocrine Carcinoma of the
Gastrointestinal Tract. |
Phase 2 |
Houston, TX, US |
|
|
|
|
|
|
PA-7551 |
Phase
II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic
/ Unresectable Neuroendocrine Tumors. |
Phase 2 |
Stanford, CA, US |
|
|
|
|
|
|
PA-7553 |
Phase
II Study of Pazopanib Hydrochloride in Patients With Low- or
Intermediate-Grade Advanced Neuroendocrine Carcinoma. |
Phase 2 |
Boston, MA, US
Houston, TX, US |
|
|
|
|
|
|
PA-7554 |
An
Open Label Study to Evaluate the Effect of Avastin in Association
With Chemotherapy on Progression-Free Survival in Patients With
Progressive Advanced/Metastatic Well-Differentiated Digestive
Endocrine Tumors of the Gastrointestinal Tract. |
Phase 2 |
Angers, France
Bordeaux , France
Boulogne-Billancourt, France
Caen, France
Cambray-Les-Tours, France
Clichy, France
Dijon, France
Lille, France
Lyon, France
Marseille, France
Montpellier, France
Paris, France
Poitiers, France
Reims, France
Saint Breieuc, France
Strasbourg, France
Toulouse, France
Villejuif, France |
|
|
|
|
|
|
PA-7558 |
Phase
I Study of BB-10901 in Patients With Relapsed or Refractory Small
Cell Lung Cancer, Other Pulmonary Tumors of Neuroendocrine Origin,
Non-Pulmonary Small Cell Carcinoma, Metastatic Carcinoid Tumors,
or Other CD56-Positive Solid Tumors. |
Phase 1 |
Springfield, MA, US
Houston, TX, US
Manchester , England
Sheffield, England
Sutton, Surrey, England |
|
|
|
|
|
|
PA-7560 |
Effectiveness
of Octreotide in Patients With Metastasized Neuroendocrine Tumors
of the Midgut. |
Phase 3 |
Marburg, Germany |
|
|
|
|
|
|
PA-7561 |
Prospective
Evaluation Study of Tumor Angiogenesis in Patients With Endocrine
Neoplasms. |
Unspecified |
Bethesda, MD, US |
|
|
|
|
|
|
PA-7563 |
Phase
1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant
Pheochromocytoma/Paraganglioma. |
Phase 2 |
Durham, NC, US
New York , NY, US
Providence, RI, US |
|
|
|
|
|
|
PA-7564 |
A
Study Of Sunitinib Compared To Placebo For Patients With Advanced
Pancreatic Islet Cell Tumors. |
Phase 3 |
Iowa City, IA, US
Jeffersonville , IN, US
Louisville, KY, US
Shelbyville, KY, US
Worcester, MA, US
St. Peters, MO, US
Creve Coeur, MO, US
St Louis , MO, US
Austin, TX, US
Georgetown, TX, US
Norfolk, VA, US
Redcliffe, Queensland, Australia
Kogarah, New South Wales, Australia
Perth, Western Australia, Australia
Brussels, Belgium
Halifax, Nova Scotia, Canada
Toronto, Ontario, Canada
Vancouver, British Columbia, Canada
Montreal, QC, Canada
Santafe de Bogota, Colombia
Liverpool, England
Bordeaux , France
Clichy Cedex, France
Lyon, France
Marseille, France
Paris, France
Heidelberg, Germany
Luebeck, Germany
Bad Berka, Germany
Berlin, Germany
Ulm, Germany
Rozzano , Italy
Barcelona, Spain
Madrid, Spain
Navarra, Spain |
|
|
|
|
|
|
PA-7588 |
Phase
II Study of Sunitinib Malate Following Hepatic Artery Embolization
for Metastatic Gastrointestinal Neuroendocrine Tumors. |
Phase 2 |
Tampa, FL, US |
|
|
|
|
|
|
PA-7680 |
A
Randomized Double-Blind Phase III Study of RAD001 10 mg/d Plus
Best Supportive Care Versus Placebo Plus Best Supportive Care
in the Treatment of Patients With Advanced Pancreatic Neuroendocrine
Tumor (NET). |
Phase 3 |
Mobile, AL, US
Anaheim, CA, US
Los Angeles, CA, US
San Francisco, CA, US
Denver, CO, US
Iowa City, IA, US
Indianapolis, IN, US
Louisville , KY, US
Rochester, MN, US
Charlotte, NC, US
Littleton, NH, US
Morristown, NJ, US
Columbus, OH, US
Portland, OR, US
Bethlehem, PA, US
Philadelphia, PA, US
Fort Worth, TX, US
Houston, TX, US |
|
|
|
|
|
|
PA-7681 |
Safety
and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine
Tumors. |
Phase 2 |
Kenner , LA, US |
|
|
|
|
|
|
PA-7723 |
Efficacy
Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine
Tumors. |
Phase 2 |
Toronto, ON, Canada |
|
|
|
|
|
|
PA-7724 |
Exploratory
Study of Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced
Low or Intermediate Grade Neuroendocrine Carcinoma. |
Phase 2 |
Houston, TX, US |
|
|
|
|
|
|
PA-7725 |
A
Phase I Trial of the mTOR Inhibitor RAD001 in Combination With
VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients
With Advanced Solid Tumors. |
Phase 1 |
Rochester, MN, US |
|
|
|
|
|
|
PA-7726 |
An
Open Lable Phase II Study Evaluating the Safety and Efficacy
of PTK787/ZK222584 in Patients With Metastatic Neuroendocrine
Tumors That Have Evidence of Progressive Disease or an Increase
in Disease Related Syndrome Symptoms. |
Phase 2 |
Iowa City, IA, US |
|
|
|
|
|
|
PA-7735 |
A
Phase II Clinical and Biological Study of Lithium Carbonate in
Patients With Low-Grade Neuroendocrine Tumors. |
Phase 2 |
Madison, WI, US |
|
|
|
|
|
|
PA-7736 |
Octreotide
and Interferon Alfa-2b or Bevacizumab in Treating Patients With
Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor.
|
Phase 3 |
Mobile, AL, US
Fort Smith, AR, US
Los Angeles, CA, US
San Diego, CA, US
Washington, DC, US
Peoria, IL, US
Baltimore, MD, US |
